Gilead Sciences (NASDAQ:GILD) CFO Andrew Dickinson Sells 3,000 Shares of Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CFO Andrew Dickinson sold 3,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $140.96, for a total transaction of $422,880.00. Following the transaction, the chief financial officer owned 176,191 shares in the company, valued at $24,835,883.36. The trade was a 1.67% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gilead Sciences Trading Down 0.9%

NASDAQ GILD opened at $138.55 on Friday. Gilead Sciences, Inc. has a 12-month low of $93.37 and a 12-month high of $157.29. The company has a fifty day simple moving average of $144.65 and a two-hundred day simple moving average of $131.10. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. The stock has a market cap of $171.97 billion, a P/E ratio of 20.47, a P/E/G ratio of 1.86 and a beta of 0.39.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. During the same period in the previous year, the company earned $1.90 earnings per share. The business’s quarterly revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, March 30th. Shareholders of record on Friday, March 13th were paid a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.4%. The ex-dividend date was Friday, March 13th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s dividend payout ratio (DPR) is presently 48.45%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. The Goldman Sachs Group lifted their target price on Gilead Sciences from $110.00 to $115.00 and gave the stock a “neutral” rating in a report on Thursday, January 8th. UBS Group increased their price target on shares of Gilead Sciences from $145.00 to $155.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Barclays began coverage on shares of Gilead Sciences in a research report on Friday, February 20th. They set an “equal weight” rating and a $155.00 price target for the company. Leerink Partners upped their price objective on shares of Gilead Sciences from $146.00 to $148.00 and gave the company an “outperform” rating in a report on Wednesday, February 11th. Finally, Royal Bank Of Canada increased their price objective on shares of Gilead Sciences from $118.00 to $123.00 and gave the stock a “sector perform” rating in a research note on Tuesday, April 7th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $156.77.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Wells Fargo reiterated a buy rating on Gilead, supporting investor confidence in the company’s longer-term fundamentals. Wells Fargo Sticks to Their Buy Rating for Gilead Sciences (GILD)
• Positive Sentiment: The U.S. Department of State expanded a partnership with Gilead and The Global Fund to provide 1 million doses of lenacapavir, boosting addressable market and public-health visibility for Gilead’s HIV prevention franchise. US-Led Partnership To Provide 1 Mln Lenacapavir To Help End HIV Transmission
• Positive Sentiment: Citigroup coverage remains constructive, with at least one analyst publicly saying GILD’s stock is expected to rise — a counterbalance to short‑term caution. Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Citigroup Analyst Says
• Neutral Sentiment: Two insiders (including the CFO) sold small percentages of their positions via pre‑arranged Rule 10b5‑1 plans; such trades signal liquidity-taking rather than new negative information. SEC Form 4 (Andrew D. Dickinson)
• Neutral Sentiment: Gilead is expected to report quarterly results soon, which typically increases volatility as investors position around guidance and product trends. Gilead Sciences (GILD) Expected to Announce Quarterly Earnings on Thursday
• Neutral Sentiment: Media and analyst coverage (valuation pieces and trending‑stock notes) are driving attention but not yet altering fundamentals. Gauging Gilead Sciences (GILD) Valuation After Strong Multi‑Year Shareholder Returns
• Negative Sentiment: RBC reported that persistence for Gilead’s HIV drug nine months after launch is weaker than expected — a potential hit to longer‑term revenue/kicker assumptions for the new product. Gilead Sciences’ HIV Drug Shows Weaker-Than-Expected Persistence Nine Months After Launch, RBC Says
• Negative Sentiment: Zacks Research trimmed Q1–Q4 FY2026 EPS forecasts, lowering near‑term earnings expectations and increasing downside risk to consensus estimates. Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
• Negative Sentiment: Broader health‑care stocks were softer late in the session, which amplified downward pressure on Gilead despite some stock‑specific positives. Sector Update: Health Care Stocks Decline Late Afternoon

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. FARMERS & MERCHANTS TRUST Co OF LONG BEACH acquired a new position in shares of Gilead Sciences in the first quarter worth about $229,000. Capital Advisors Ltd. LLC increased its stake in shares of Gilead Sciences by 6.2% in the 1st quarter. Capital Advisors Ltd. LLC now owns 1,431 shares of the biopharmaceutical company’s stock valued at $199,000 after purchasing an additional 83 shares in the last quarter. Sterling Investment Counsel LLC raised its holdings in Gilead Sciences by 33.5% in the 1st quarter. Sterling Investment Counsel LLC now owns 8,808 shares of the biopharmaceutical company’s stock worth $1,228,000 after purchasing an additional 2,210 shares during the period. Smith Salley Wealth Management acquired a new position in Gilead Sciences in the 1st quarter worth about $206,000. Finally, True Vision MN LLC purchased a new position in Gilead Sciences during the first quarter worth approximately $622,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.